BlossomHill Therapeutics, Inc. develops precision medicines targeting oncology and autoimmune disorders by utilizing advanced drug design techniques and human intelligence. The company aims to create therapies that overcome the limitations of existing treatments, improving patient outcomes in these challenging medical areas.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CVFounders
Product
Problem
Existing treatments for oncology and autoimmune disorders often have limitations, leading to suboptimal patient outcomes. There is a need for more precise and effective therapies that can overcome these limitations and improve patient outcomes in these challenging medical areas.
Solution
BlossomHill Therapeutics develops precision medicines for oncology and autoimmune disorders using advanced drug design techniques and human intelligence. The company focuses on creating therapies that address the shortcomings of current treatments. By combining human expertise with innovative drug design, BlossomHill aims to tackle significant challenges in oncology and autoimmune diseases, developing medicines from the ground up to improve patient outcomes. Their pipeline includes novel therapies designed to overcome the limitations of existing treatments.
Target Audience
The primary target audience includes patients with oncology and autoimmune disorders, as well as healthcare professionals seeking more effective treatment options.
Features
- Utilizes advanced drug design techniques
- Focuses on precision medicines for oncology and autoimmune disorders
- Employs human intelligence and creative thinking in drug development
- Developing BH-30236 and BH-30643, novel therapies designed to overcome the limitations of existing treatments
- BH-30643 is an OMNI-EGFR™ inhibitor
- Phase 1/2 SOLARA clinical trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer is underway